Analyst: Time to Sell This Penny Stock

Most analysts are bullish on the biopharma

Jul 16, 2019 at 9:44 AM
facebook twitter linkedin

B. Riley FBR downgraded Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to "sell" from "neutral," and lowered its price target to $1.10 from $1.90 -- a 25% discount to last night's close. In reaction, the penny stock has plunged 4.1% out of the gate to trade at $1.40.

It's already been a tough stretch for the shares of the EpiPen rival, which were down almost 64% year-over-year heading into today's trading. More recently, the stock's rebound off its July 2 record low of $1.20 was quickly contained by familiar resistance at its descending 50-day moving average.

Nevertheless, the majority of the analysts in coverage still maintain a "buy" or better rating on the biopharmaceutical name. Plus, the average 12-month price target sits all the way up at $171.92. More bear notes could be in store for the underperformer.

Elsewhere on the sentiment front, short sellers have been increasing their exposure to the struggling stock. Year-to-date, short interest on ADMP is up 13.4% to 4.08 million shares. This accounts for a healthy 8.7% of the security's available float, or 12.9 times the average daily pace of trading. These bears are sidelined today, though, with the equity on the short-sale restricted list.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners